Optibrium and AstraZeneca sign agreement for global license of StarDrop

 

Optibrium, a developer of software for drug discovery, todayannounced that AstraZeneca has signed an agreement to license Optibrium'sStarDrop software.  The agreement willsee the global deployment of StarDrop and the ADME-QSAR and Auto-Modellermodules to AstraZeneca's researchers. StarDrop is a software suite that helpsto deliver optimally balanced, effective drugs. By quickly highlightingdiverse, high-quality compounds, StarDrop dramatically reduces the time ittakes to find effective leads and then transform them into candidate drugs,which will have a high probability of success downstream.